SciSparc, Clearmind announce publication of U.S. patent application

SciSparc (SPRC) announced that its collaboration with Clearmind Medicine (CMND) has led to the publication of a U.S. patent application by the United States Patent and Trademark Office. The patent relates to an innovative combination therapy of MEAI and N-Acylethanolamines, such as Palmitoylethanolamide, addressing binge behavior disorders. The patent refers to multiple binge behaviors, including excessive alcohol consumption, eating disorders, tobacco use, compulsive shopping, and problematic sexual conduct. The combination leverages MEAI’s psychedelic properties to reduce impulsivity and reward-seeking, enhanced by PEA’s anti-inflammatory and neuroprotective effects, potentially offering a breakthrough in treating substance use and behavioral addictions without the risks associated with traditional interventions. SciSparc-Clearmind collaboration, focusing on PEA-MEAI combinations for conditions such as alcohol use disorder, cocaine addiction, obesity, and depression. Preclinical data supports the therapy’s potential efficacy in mitigating binge episodes while preserving natural reward pathways.